Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Among authors: klingbiel d. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.
Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S. Missiaglia E, et al. Among authors: d ario g, klingbiel d. Ann Oncol. 2014 Oct;25(10):1995-2001. doi: 10.1093/annonc/mdu275. Epub 2014 Jul 23. Ann Oncol. 2014. PMID: 25057166 Free article.
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.
Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann KP, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S. Fischer S, et al. Among authors: klingbiel d. J Clin Oncol. 2017 Jan 10;35(2):194-200. doi: 10.1200/JCO.2016.69.0958. Epub 2016 Nov 28. J Clin Oncol. 2017. PMID: 27893332 Free article.
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK). Pagani O, et al. Among authors: klingbiel d. Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622. Ann Oncol. 2017. PMID: 27998961 Free article. Clinical Trial.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T. Schmid S, et al. Among authors: klingbiel d. BMC Cancer. 2019 Sep 10;19(1):902. doi: 10.1186/s12885-019-6105-3. BMC Cancer. 2019. PMID: 31500588 Free PMC article. Clinical Trial.
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.
Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S; Global Germ-Cell Cancer Group. Fischer S, et al. Among authors: klingbiel d. J Clin Oncol. 2020 Apr 20;38(12):1322-1331. doi: 10.1200/JCO.19.01876. Epub 2019 Dec 26. J Clin Oncol. 2020. PMID: 31877087 Free PMC article.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro L, Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J, Machackova Z, Stamatovic L; PHranceSCa study group. O'Shaughnessy J, et al. Among authors: klingbiel d. Eur J Cancer. 2021 Jul;152:223-232. doi: 10.1016/j.ejca.2021.03.047. Epub 2021 Jun 16. Eur J Cancer. 2021. PMID: 34147014 Free article. Clinical Trial.
65 results